Please login to the form below

Not currently logged in
Email:
Password:

Zealand adds two observers to board of directors

Martin Nicklasson and Catherine Moukheibir join the firm
Martin Nicklasson

Denmark-based pharma company Zealand Pharma has added Dr Martin Nicklasson and Catherine Moukheibir the company's board of directors in the role of observers.

The announcement comes just days after the pharma company revealed Britt Meelby Jensen as its new CEO.

Nicklasson has held various executive VP positions at AstraZeneca and was president and CEO of BioVitrum and Swedish Orphan Biovitrum. He is also chairman of the board of Basilea, Orexo and Farma Holding.

Catherine Moukheibir has held senior management positions in several European biotech companies after an initial career in strategy consulting and investment banking. She is currently a non-executive board member of Creabilis and Ablynx.

Daniel Ellens, chairman of the Zealand board of directors, said: “They provide important and broad-based experience from public life science companies and are important additions to the competences on the board as we prepare for the next steps in Zealand's growth strategy as a maturing biotech company.”

12th November 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics